Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dupilumab - Regeneron/Sanofi

Drug Profile

Dupilumab - Regeneron/Sanofi

Alternative Names: Dupixent; REGN-668; SAR-231893

Latest Information Update: 04 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals; sanofi-aventis
  • Developer Aimmune Therapeutics; Regeneron Pharmaceuticals; Sanofi
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Monoclonal antibodies; Skin disorder therapies
  • Mechanism of Action Interleukin 13 inhibitors; Interleukin 4 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Eosinophilic oesophagitis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Asthma; Atopic dermatitis; Nasal polyps
  • Phase III Chronic obstructive pulmonary disease; Eosinophilic oesophagitis
  • Phase II Grass pollen hypersensitivity; Peanut hypersensitivity; Prostate cancer; Urticaria
  • Phase I Allergic asthma

Most Recent Events

  • 20 Nov 2019 Regeneron and Sanofi plans the phase III CUPID trial for Urticaria (Treatment-experienced, In children, In adolescents, In adults, In the elderly) (SC) (NCT04180488)
  • 05 Nov 2019 Regeneron and Sanofi plans the phase III PRIME trial for Prurigo nodularis
  • 05 Nov 2019 Regeneron announces intention to submit a Marketing Authorisation Application (MAA) to the EMA for Atopic dermatitis (In children) in by the end of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top